RespireRx Pharmaceuticals Inc. Announces Publication of Book Chapter Describing Novel Analgesic Properties of KRM-II-81
November 30, 2021 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of AMPAkines in the Treatment of Human Spinal Cord Injury
November 29, 2021 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces CEO’s OTC Venture Market Podcast
November 22, 2021 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), (“RespireRx” or the “Company”) a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. to Present in June 2021 Access China Biotech Virtual Investor Conference
June 08, 2021 18:20 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces New Data Regarding the Use of AMPAkines as Potential Treatments for Spinal Cord Injury
May 12, 2021 09:15 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs
April 22, 2021 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces Appointment of Timothy Jones as President and Chief Executive Officer
May 06, 2020 09:25 ET
|
RespireRX Pharmaceuticals Inc.
Dr. Arnold S. Lippa, Ph.D. to Continue as Executive Chairman of the Board of Directors and Chief Scientific Officer Glen Rock, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc....
RespireRx Pharmaceuticals Inc. CEO Issues Progress and Status Report
February 12, 2020 09:15 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 12, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), a leader in the development of medicines for respiratory disorders and central nervous system (“CNS”)...
RespireRx Pharmaceuticals Inc. Announces the Filing of Broad Enabling Cannabinoid Continuation-in-Part and New Provisional Patent Applications
February 05, 2020 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 05, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...